Zanidatamab is a bispecific antibody that binds to 2 non-overlapping extracellular epitopes of the HER2 receptor.

Jazz Pharmaceuticals plc announced the US Food and Drug Administration (FDA) accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults ...

The US Food and Drug Administration (FDA) has granted accelerated approval to Ziihera (zanidatamab-hrii) for the treatment of adults with previously treated, unresectable or metastatic HER2-positive ...

GLP-1 RAs to assist with weight loss have exploded in popularity. Researchers are working to identify which patients will benefit from them and their associated risks.

Jazz Pharmaceuticals has claimed FDA approval for its HER2-directed bispecific antibody Ziihera as a treatment for biliary tract cancer (BTC), the first in a series of potential indications that the ...

Currently, chemotherapy remains a common treatment for biliary tract cancers, which have a limited survival rate.

Ziihera is the first dual HER2-targeted bispecific antibody approved in the U.S. for HER2-positive biliary tract cancer ...

Learn more about a new treatment for biliary tract cancers with high levels of HER2. The drug zanidatamab has been approved ...

Jazz Pharmaceuticals JAZZ announced that the FDA has granted accelerated approval to its intravenously administered drug ...

The US Food and Drug Administration (FDA) has granted accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for ...

Jazz Pharmaceuticals says the U.S. Food and Drug Administration has approved use of the tumor-fighting antibody to treat adults with a form of biliary-tract cancer (BTC) ...

The agency has approved Ziihera for adults with previously treated, unresectable or metastatic HER2-positive biliary tract ...